Jacek Jassem

发表

Yolande Lievens, Galina Velikova, Mark Lawler, 2021, Journal of cancer policy.

David Cameron, Pascale Anderle, Thierry Petit, 2009, Nature Medicine.

Cardiovascular effects of breast cancer radiotherapy.

Jacek Jassem, J. Jassem, Elzbieta Senkus-Konefka, 2007, Cancer treatment reviews.

Caring for relatives with lung cancer in Europe: an evaluation of caregivers’ experience

Jacek Jassem, J. Jassem, J. Penrod, 2015, Quality of Life Research.

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.

Nick Thatcher, Shengyan Hong, Jacek Jassem, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung

Marcin Skrzypski, Ewa Jassem, Witold Rzyman, 2008, Clinical Cancer Research.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Josep Tabernero, Jean-Yves Douillard, David Cunningham, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.

Tanja Cufer, Thierry Petit, Khalil Zaman, 2011, The Lancet. Oncology.

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

Julio Astudillo, Jean-Yves Douillard, Vito Lorusso, 2006, The Lancet. Oncology.

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.

Tudor Ciuleanu, Jacek Jassem, R. Ramlau, 2006, Lung cancer.

An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer

Marcin Skrzypski, Witold Rzyman, Thomas Muley, 2009, Clinical Cancer Research.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Jianying Zhou, Erdem Goker, Jun Zhao, 2019, The Lancet.

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

Scott D. Patterson, Josep Tabernero, Jean-Yves Douillard, 2013 .

Intraoperative, radio-guided sentinel lymph node mapping in 110 nonsmall cell lung cancer patients.

Rafal Dziadziuszko, Witold Rzyman, Jacek Jassem, 2006, The Annals of thoracic surgery.

Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer.

Ewa Jassem, Witold Rzyman, Dariusz Tomaszewski, 2009, Lung cancer.

Radiotherapy-induced thyroid disorders.

Roberto Orecchia, Daniela Alterio, Barbara A Jereczek-Fossa, 2004, Cancer treatment reviews.

Cancer clinical trials in Central and Eastern Europe: historical review.

Jacek Jassem, M. Krzakowski, J. Jassem, 2002, Critical reviews in oncology/hematology.

Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes.

Marcin Skrzypski, Amelia Szymanowska-Narloch, Ewa Jassem, 2013, Clinical lung cancer.

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

Tomasz Burzykowski, Marc Buyse, Laura Biganzoli, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning.

Grant Lewison, Tanja Cufer, Mark Lawler, 2018, European journal of cancer.